Tetsuya Mitsudomi

61.8k total citations · 13 hit papers
529 papers, 36.6k citations indexed

About

Tetsuya Mitsudomi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Tetsuya Mitsudomi has authored 529 papers receiving a total of 36.6k indexed citations (citations by other indexed papers that have themselves been cited), including 400 papers in Pulmonary and Respiratory Medicine, 277 papers in Oncology and 151 papers in Molecular Biology. Recurrent topics in Tetsuya Mitsudomi's work include Lung Cancer Treatments and Mutations (344 papers), Lung Cancer Diagnosis and Treatment (138 papers) and Lung Cancer Research Studies (107 papers). Tetsuya Mitsudomi is often cited by papers focused on Lung Cancer Treatments and Mutations (344 papers), Lung Cancer Diagnosis and Treatment (138 papers) and Lung Cancer Research Studies (107 papers). Tetsuya Mitsudomi collaborates with scholars based in Japan, United States and United Kingdom. Tetsuya Mitsudomi's co-authors include Yasushi Yatabe, Takashi Takahashi, Takayuki Kosaka, Hideki Endoh, Kenichi Suda, Toyoaki Hida, Hiroyuki Kuwano, Hirotaka Osada, Yoshihisa Kobayashi and Shuta Tomida and has published in prestigious journals such as Science, New England Journal of Medicine and The Lancet.

In The Last Decade

Tetsuya Mitsudomi

508 papers receiving 35.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

2007 3.6k citations Jeffrey A. Engelman, Kreshnik Zejnullahu et al. Science profile →
Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival

2004 1.9k citations Junichi Takamizawa, Hiroyuki Konishi et al. Cancer Research profile →
Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer

2004 1.0k citations Takayuki Kosaka, Yasushi Yatabe et al. Cancer Research profile →
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

2010 915 citations Yasushi Yatabe, Tetsuya Mitsudomi et al. profile →
Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence

2005 830 citations Tetsuya Mitsudomi, Takayuki Kosaka et al. Journal of Clinical Oncology profile →
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial

2022 764 citations Morihito Okada, Masahiro Tsuboi et al. profile →
Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas.

1998 718 citations Toyoaki Hida, Yasushi Yatabe et al. profile →
Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations

2008 513 citations Seiji Yano, Wei Wang et al. Cancer Research profile →
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study

2016 502 citations Toyoaki Hida, Helen Mann et al. profile →
A Prospective Radiological Study of Thin-Section Computed Tomography to Predict Pathological Noninvasiveness in Peripheral Clinical IA Lung Cancer (Japan Clinical Oncology Group 0201)

2011 464 citations Tetsuya Mitsudomi, Masahiro Tsuboi et al. profile →
Comparison of pulmonary segmentectomy and lobectomy: Safety results of a randomized trial

2019 310 citations Morihito Okada, Masahiro Tsuboi et al. profile →
A single-arm study of sublobar resection for ground-glass opacity dominant peripheral lung cancer

2020 198 citations Ichiro Yoshino, Masahiro Tsuboi et al. profile →
KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments

2021 167 citations Kenichi Suda, Toshio Fujino et al. profile →

Peers

Tetsuya Mitsudomi

PRM

ONCOL

RNMI

Jean‐Charles Soria France

Stéphane Oudard France

Vincent A. Miller United States

William Pao United States

Yasushi Yatabe Japan

Fortunato Ciardiello Italy

Ronald M. Bukowski United States

Ignacio I. Wistuba United States

David R. Gandara United States

Walter M. Stadler United States

Jean‐Charles Soria France

Tetsuya Mitsudomi

12.8k ×0.6

PRM

19.7k ×1.1

ONCOL

13.0k ×0.9

6.8k ×0.8

2.6k ×1.0

RNMI

Citations per year, relative to Tetsuya Mitsudomi Tetsuya Mitsudomi (= 1×) peers Jean‐Charles Soria

Countries citing papers authored by Tetsuya Mitsudomi

Since Specialization

Citations

This map shows the geographic impact of Tetsuya Mitsudomi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tetsuya Mitsudomi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tetsuya Mitsudomi more than expected).

Fields of papers citing papers by Tetsuya Mitsudomi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tetsuya Mitsudomi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tetsuya Mitsudomi. The network helps show where Tetsuya Mitsudomi may publish in the future.

Co-authorship network of co-authors of Tetsuya Mitsudomi

This figure shows the co-authorship network connecting the top 25 collaborators of Tetsuya Mitsudomi. A scholar is included among the top collaborators of Tetsuya Mitsudomi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tetsuya Mitsudomi. Tetsuya Mitsudomi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Suda, Kenichi, Akira Hamada, Toshio Fujino, et al.. (2025). Efficacy of Conventional and Novel Tyrosine Kinase Inhibitors for Uncommon EGFR Mutations—An In Vitro Study. Cells. 14(17). 1386–1386.

Spicer, Jonathan, Nicolas Girard, Mariano Provencio, et al.. (2024). Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816.. Journal of Clinical Oncology. 42(17_suppl). LBA8010–LBA8010. 25 indexed citations

Suda, Kenichi, Akira Hamada, Shuta Ohara, et al.. (2024). Potential Utility of a 4th-Generation EGFR-TKI and Exploration of Resistance Mechanisms—An In Vitro Study. Biomedicines. 12(7). 1412–1412. 6 indexed citations

Heymach, John V., David H. Harpole, Tetsuya Mitsudomi, et al.. (2023). Abstract CT005: AEGEAN: A phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC. Cancer Research. 83(8_Supplement). CT005–CT005. 55 indexed citations

Kenmotsu, Hirotsugu, Nobuyuki Yamamoto, Toshihiro Misumi, et al.. (2023). Five-Year Overall Survival Analysis of the JIPANG Study: Pemetrexed or Vinorelbine Plus Cisplatin for Resected Stage II-IIIA Nonsquamous Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 41(34). 5242–5246. 8 indexed citations

Hamada, Akira, Junichi Soh, Akito Hata, et al.. (2021). Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage IIIA-B (Discrete N2) Non–small-cell Lung Cancer: SQUAT trial (WJOG 12119L). Clinical Lung Cancer. 22(6). 596–600. 12 indexed citations

Suda, Kenichi, Isao Murakami, Hui Yu, et al.. (2018). CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer. Molecular Cancer Therapeutics. 17(10). 2257–2265. 39 indexed citations

Kobayashi, Yoshihisa, Koichi Azuma, Hiroki Nagai, et al.. (2016). Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer. Molecular Cancer Therapeutics. 16(2). 357–364. 57 indexed citations

Terashima, Masato, Yosuke Togashi, Katsuaki Sato, et al.. (2016). Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non–Small Cell Lung Cancer: Double-Edged Sword of DDR2. Clinical Cancer Research. 22(14). 3663–3671. 15 indexed citations

10.

Kobayashi, Yoshihisa, Yosuke Togashi, Yasushi Yatabe, et al.. (2015). EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs. Clinical Cancer Research. 21(23). 5305–5313. 164 indexed citations

11.

Nakagawa, Takayuki, Shinji Takeuchi, Tadaaki Yamada, et al.. (2012). Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR -Mutant Lung Cancer. Molecular Cancer Therapeutics. 11(10). 2149–2157. 74 indexed citations

12.

Yanagisawa, Kiyoshi, Hiroyuki Konishi, Chinatsu Arima, et al.. (2010). Novel Metastasis-Related Gene CIM Functions in the Regulation of Multiple Cellular Stress–Response Pathways. Cancer Research. 70(23). 9949–9958. 22 indexed citations

13.

Suda, Kenichi, Isao Murakami, Tatsuya Katayama, et al.. (2010). Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer. Clinical Cancer Research. 16(22). 5489–5498. 170 indexed citations

14.

Ebi, Hiromichi, Shuta Tomida, Toshiyuki Takeuchi, et al.. (2009). Relationship of Deregulated Signaling Converging onto mTOR with Prognosis and Classification of Lung Adenocarcinoma Shown by Two Independent In silico Analyses. Cancer Research. 69(9). 4027–4035. 31 indexed citations

15.

Yano, Seiji, Wei Wang, Qi Li, et al.. (2008). Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations. Cancer Research. 68(22). 9479–9487. 513 indexed citations breakdown →

16.

Engelman, Jeffrey A., Kreshnik Zejnullahu, Tetsuya Mitsudomi, et al.. (2007). MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling. Science. 316(5827). 1039–1043. 3570 indexed citations breakdown →

17.

Tanaka, Hisaaki, Kiyoshi Yanagisawa, Keiko Shinjo, et al.. (2007). Lineage-Specific Dependency of Lung Adenocarcinomas on the Lung Development Regulator TTF-1. Cancer Research. 67(13). 6007–6011. 165 indexed citations

18.

Takamizawa, Junichi, Hiroyuki Konishi, Kiyoshi Yanagisawa, et al.. (2004). Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival. Cancer Research. 64(11). 3753–3756. 1938 indexed citations breakdown →

19.

Carbone, David P., Tetsuya Mitsudomi, Itsuo Chiba, et al.. (1994). p53 Immunostaining Positivity Is Associated With Reduced Survival and Is Imperfectly Correlated With Gene Mutations in Resected Non-small Cell Lung Cancer. CHEST Journal. 106(6). 377S–381S. 92 indexed citations

20.

Felix, Carolyn A., D D’Amico, Tetsuya Mitsudomi, et al.. (1992). Absence of hereditary p53 mutations in 10 familial leukemia pedigrees.. Journal of Clinical Investigation. 90(2). 653–658. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact